No abstract

AimThe objective of this study was to evaluate the Chinese version of the Smartphone Distraction Scale (C-SDS), which is an easy-to-use tool for screening the risk of smartphone distraction in Chinese college students.MethodsThe C-SDS, Smartphone Addiction Scale - Short Version (SAS-SV), Fear of Missing Out scale (FoMO) and Metacognition about Smartphone Use Questionnaire (MSUQ) were used in a sample of 1,002 Chinese college students to test smartphone distraction and its influencing factors. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) were performed to test measurement properties and factor structures of the C-SDS. Multi-variable linear regressions examined the relationships of sex, age, education level, the purpose of using a smartphone, usage of smartphone (hours per day), fear of missing out, smartphone addiction and positive and negative metacognitions about smartphone use with the C-SDS.ResultsThe EFA showed a 3-factor structure, which consisted of attention impulsiveness, multitasking and emotion regulation. The CFA showed that the 3-factor demonstrated an overall better model fit (RMSEA = 0.07, SRMR = 0.05, CFI = 0.94, TLI = 0.93). The C-SDS showed internal consistency (Cronbach’s α = 0.88, McDonald’s Omega ω = 0.88). Findings included that negative metacognition about smartphone use was most correlated with the C-SDS (b = 0.73; p < 0.001). Smartphone addiction, positive metacognition about smartphone use and fear of missing out also correlated with the C-SDS (b = 0.66, p < 0.001; b = 0.53, p < 0.001; b = 0.40, p < 0.001, respectively). The study shows that males compared to females (b = –1.65; p = 0.003), had a higher C-SDS score.ConclusionThe C-SDS was valid and reliable for assessing the distraction of using smartphones in the Chinese context. Being female, the purpose of using a smartphone, smartphone usage (hours per day), fear of missing out, smartphone addiction and positive and negative metacognitions about smartphone use were positively correlated to the C-SDS.

No abstract

Background Depression affects 10%–20% of older adults worldwide. The course of late‐life depression (LLD) is often chronic, with a poor long‐term prognosis. Lower treatment adherence, stigma, and suicide risk lead to significant challenges in the continuity of care (COC) for patients with LLD. Elderly patients with chronic diseases can benefit from COC. As a common chronic disease of the elderly, whether depression can also benefit from COC has not been systematically reviewed. Methods Systematic literature search in Embase, Cochrane Library, Web of Science, Ovid, PubMed and Medline. Randomized Controlled Trials (RCTs) on the intervention effects of COC and LLD, published on 12 April 2022, were selected. Two independent researchers made research choices based on consensus. An RCT with COC as an intervention measure for the elderly with depression 60 years old was the inclusion criteria. Results A total of 10 RCTs involving 1557 participants were identified in this study. The findings showed that: (1) COC significantly reduced depressive symptoms compared to usual care (standardized mean difference [SMD] = −0.47, 95% confidence interval: −0.63 to −0.31), with the best improvement at 3‐ to 6‐month follow‐up; (2) The reduction in depressive symptoms was more pronounced for patients with comorbid chronic conditions with LLD (SMD = −0.93, 95% CI: −1.18 to −0.68); (3) COC was more effective than other regions for LLD in Europe and the Americas (SMD = −0.84, 95% CI: −1.07 to −0.61); and (4) COC had a positive impact on the quality of life of patients with LLD (SMD = 0.21, 95% CI: 0.02–0.40). Limitations The included studies included several multi‐component interventions with widely varying methods. Therefore, it was almost impossible to analyze which of these interventions had an impact on the assessed outcomes. Conclusions This meta‐analysis shows that COC can significantly reduce depressive symptoms and improve quality of life in patients with LLD. However, when treating and caring for patients with LLD, health care providers should also pay attention to timely adjustments of intervention plans according to follow‐up, synergistic interventions for multiple co‐morbidities, and actively learning from advanced COC programs at home and abroad to improve the quality and effectiveness of services.

BACKGROUND Depression is the most common psychiatric disorder among older adults. Telecare has been shown to be effective in addressing patients' psychosocial issues and improving their Quality of Life (QoL), while its efficacy in serving individuals with Late-Life Depression (LLD) remains unclear. This study aimed to assess the effectiveness of telecare in reducing depression and anxiety symptoms and improving the quality of life in patients with LLD. OBJECTIVE To evaluate the effectiveness of telecare interventions in reducing depression and anxiety symptoms, and improving QoL in patients with LLD. METHODS Databases including the Cochrane Library, Web of Science (SCI), PubMed, Embase, and EBSCO were searched for randomized controlled trials (RCTs) evaluating the effectiveness of telecare for LLD from database establishment to December 28, 2022. RESULTS Twelve studies involving 2,255 older participants were included. The results of the meta-analysis showed that the depression level of the telecare intervention group was significantly reduced (Standardized Mean Difference (SMD = -0.39, 95% Confidence Interval (CI): -0.47 to -0.31, P < .001), and the short-term intervention on Mental Component of QoL had a significant effect (SMD = 0.15, 95% CI:0.04 to 0.26, P = 0.04). There is no statistically significant effect on alleviating anxiety symptoms in LLD (SMD= -0.34, 95% CI: -0.54 to -0.14, P= 0.12). CONCLUSIONS Telecare is a promising modality of care for the treatment of patients with LLD, which can alleviate depression and improve the QoL of LLD patients. Continued in-depth research into the effectiveness of telecare in depression could better identify where older patients would benefit from this intervention. CLINICALTRIAL None